CLINICAL AND PATHOLOGICAL CHARACTERISTICS OF RECURRENT INVASIVE BREAST CANCER

Dang Quynh Le1,, Hong Phong Nguyen2, Duong Quoc Uy Au3
1 Can Tho Gynecology Obstetrics Hospital
2 Can Tho University of Medicine and Pharmacy
3 Pham Ngoc Thach University of Medicine

Main Article Content

Abstract

Background: Currently, about 40% of breast cancer patients have recurrence and most of these cases have high mortality rates. Objective: To describe the clinical and anatomical characteristics of recurrent invasive breast cancer. Materials and methods: Prospective crosssectional descriptive study of medical records and biopsy specimens of 146 female patients with recurrent invasive breast cancer at Can Tho City Oncology Hospital since January June 2023 to March 2024. Results: Most breast cancer patients relapse in the first 5 years after treatment (accounting for 76.7%), especially in the first 3 years. Clinical characteristics: the most common type of recurrence was distant metastasis (73.3%), often metastases to more than 1 organ (57.9%), the most common site of metastasis was bone (29.5%), lung (28.8%), liver (22.6%). Histopathological characteristics: the most common histological type was the NST type (95.9%), the main histological grade was grade 2 (89%), the positive rate of ER and PR in the late recurrence group was higher than in the group with In the early recurrence group, the HER2 positive rate in the early recurrence group was higher than in the late recurrence group with p>0.05. Conclusion: Recurrent invasive breast cancer often occurs in the first 5 years after treatment, especially in the first 3 years. The most common type of recurrence is distant metastasis (mainly in the bones, lungs, and liver). The most common histological type is the non-specific type with mainly grade 2 histology. The ER and PR positive rates are higher in the late recurrence group, and the HER2 rate is higher in the early recurrence group.

Article Details

References

1. National Cancer Insstitute. SEER Cancer Statistics Review, 1975–2015. https://seer.cancer.gov/archive/csr/1975_2015/index.html
2. Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, et al. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. Journal of Clinical Oncology. 2016. 34(9), 927-935, doi:
10.1200/JCO.2015.62.3504.
3. Vũ Đình Giáp, Lê Hồng Quang, Đoàn Thị Hồng Nhật, Nguyễn Ngọc Tú, Nguyễn Khắc Tiến.
Đánh giá kết quả điều trị ung thư vú ở phụ nữ trẻ tuổi tại Bệnh viện Ung bướu Nghệ An. Tạp chí Y học Việt Nam. 2022. 100-103.
4. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology. 2013. 24(9), 2206-23. doi: 10.1093/annonc/mdt303.
5. Thân Văn Thịnh, Bùi Vinh Quang. Kết quả hóa trị Paclitaxel trong ung thư vú tái phát di căn tại bệnh viện ung bướu hà nội. Tạp chí Y học Việt Nam. 2023. 19 - 23. 6. Phùng Phướng. Đánh giá các yếu tố tiên lượng về thời gian sống thêm của ung thư vú tái phát. Tạp chí Y học Lâm sàng. 2016. 172-177.
7. Shahriari-Ahmadi A, Arabi M, Payandeh M, Sadeghi M. The recurrence frequency of breast cancer and its prognostic factors in Iranian patients. International Journal of Applied and Basic Medical Research. 2017. 40-43. doi: 10.4103/2229-516X.198521.
8. Christine AP, Katherine K, Mark GT. Breast conserving surgery and radiation as a choice for patients with BRCA mutations. Journal of Solid Tumors. 2012. 45-53, doi: 10.5430/jst.v2n5p45
9. Young JL, Seung PJ, Jeung WB, Sun MY, Ji JY et al. Prognosis according to the timing of recurrence in breast cancer. Ann Surg Treat Res. 2023. 1-9, doi: 10.4174/astr.2023.104.1.1. 10. Vũ Hồng Thăng, Đào Thị Oanh. Đặc điểm tái phát và di căn của ung thư vú có thụ thể nội tiết dương tính điều trị tamoxifen tại bệnh viện K. Tạp chí Y học Lâm sàng. 2016. 157-164.
11. Gerber B, Freund M, Reimer T. Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. Dtsch Arztebl Int. 2010. 85-91, doi: 10.3238/arztebl.2010.0085.
12. Amari M, Ishida T, Takeda M, Ohuchi N. Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer. Jpn J Clin Oncol. 2010. 188193, doi: 10.1093/jjco/hyp145.
13. Abdulwassi HK, Amer IT, Alhibshi AH, Alnajjar AA, Bahatheq AK, et al. Recurrence rates and long-term survival factors in young women with breast cancer. Saudi Med J. 2020. 393-399, doi:
10.15537/smj.2020.4.24987.